CAPTRUST Financial Advisors
KRYS icon

CAPTRUST Financial Advisors’s Krystal Biotech KRYS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
1,448
+269
+23% +$80.4K ﹤0.01% 2133
2026
Q1 		$305K Buy
1,179
+4
+0.3% +$1.06K ﹤0.01% 2374
2025
Q4 		$290K Buy
+1,175
New +$247K ﹤0.01% 2277
2022
Q3 		– Sell
-155
Closed -$10K – 3127
2022
Q2 		$10K Buy
155
+102
+192% +$6.34K ﹤0.01% 3749
2022
Q1 		$4K Sell
53
-16
-23% -$999 ﹤0.01% 4251
2021
Q4 		$5K Buy
+69
New +$4.02K ﹤0.01% 4074

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAPTRUST Financial Advisors's KRYS Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Krystal Biotech (KRYS) stake by 23% in Q2 2026, buying an estimated $80.4K and bringing the position to 1,448 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

CAPTRUST Financial Advisors first reported a position in KRYS in Q4 2021 and has held it in 6 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • CAPTRUST Financial Advisors held 1,448 shares of Krystal Biotech worth $538K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 269 Krystal Biotech shares in Q2 2026, an estimated $80.4K.
  • Krystal Biotech made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2133 holding.
  • CAPTRUST Financial Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 6 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.